The Cholangiocarcinoma Conference: Molecular Drivers, Microenvironment, and Precision Medicine

胆管癌会议：分子驱动因素、微环境和精准医学

• 批准号: 10747566
• 负责人: ALPHONSE E SIRICA
• 金额: $ 1.4万
• 依托单位: FEDERATION OF AMER SOC FOR EXPER BIOLOGY
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-08-01 至 2024-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10747566
• 关键词: Address; Adenocarcinoma; Advocate; Affect; Area; Award; Basic Science; Biological; Cholangiocarcinoma; Classification; Clinical; Clinical Management; Clinical Research; Clinical Trials; Collaborations; Colorectal Cancer; Communities; Complex; Country; Curative Surgery; Detection; Development; Diabetes Mellitus; Diagnosis; Discipline; Disease Progression; Educational workshop; Epithelium; Excision; Genomics; Goals; Hepatobiliary; Heterogeneity; Human; Immune; Immunologic Surveillance; Incidence; International; Intrahepatic Cholangiocarcinoma; Knowledge; Link; Liver parenchyma; Malignant - descriptor; Malignant Neoplasms; Malignant neoplasm of gastrointestinal tract; Mentors; Molecular; Monitor; Obesity; Oral; Pancreatic Ductal Adenocarcinoma; Pathogenesis; Patient advocacy; Patients; Persons; Pharmaceutical Preparations; Pre-Clinical Model; Prevention; Primary Malignant Neoplasm of Liver; Primary carcinoma of the liver cells; Prognosis; Research; Research Personnel; Risk Factors; Role; Scientist; Survival Rate; Talents; Translational Research; Unresectable; Viral hepatitis; advanced disease; advocacy organizations; biliary tract; biomarker signature; career; career development; collaborative environment; drug discovery; epigenomics; human model; improved; innovation; insight; interest; meetings; microbiome; mortality; multiple omics; new technology; novel; novel strategies; personalized approach; personalized immunotherapy; personalized medicine; posters; precision medicine; recruit; survival outcome; symposium; targeted agent; targeted treatment; therapeutic target; therapy resistant; trend; tumor; tumor heterogeneity; tumor microenvironment

Project Summary/Abstract Cholangiocarcinoma (CCA) is a macro-molecularly diverse hepato-biliary tract malignancy that accounts for approximately 3.0% of gastrointestinal malignancies and between 10% to 20% of primary liver cancers. Over the past 10-20 years, CCA has become the focus of heightened interest and concern, due in large part to the now well recognized increasing incidence of intrahepatic CCA in various countries around the world, as well as with CCA’s globally high mortality rates also rising in several areas of the world, including the USA. Most CCA patients are diagnosed with advanced disease, where treatment options are limited and overall, 5-year survival rates are dismal. However recent advances in a growing number of targeted therapies and clinical trials are offering some hope for improving survival outcomes for advanced CCA patients. To our knowledge, this FASEB Scientific Conference represents the first-of-its kind 4- day in person comprehensive scientific meeting solely devoted to CCA. It brings together a diverse group of senior and talented early career investigators to critically assess important areas of current and evolving basic, translational, and clinical research focused on addressing the major challenges that continue to limit progress towards achieving significant improvements in CCA prevention, clinical management, and patient survival outcomes. Key topic areas that will be addressed include (1) the challenges of inter- and intra-tumoral heterogeneity, (2) the roles of the microbiome and tumor microenvironment in affecting disease progression, therapeutic resistance, and immunosurveillance, (3) cellular origins, lineage, and genomic relationships between CCA and hepatocellular carcinoma, (4) identification of novel and more effective biomarker signatures for early CCA detection and for monitoring prognosis and treatments; (5) advances in “multi-omics” for personalizing therapies, (6) innovative preclinical modeling for CCA drug discovery, (7) current and emerging trends in CCA personalized medicine, and (8) exploring new technologies and approaches for CCA therapies. Additional important aims of this much needed conference involve providing a collegial and collaborative environment that supports early career investigator development, promotes scientific cross-talk between different scientific and clinical disciplines, mentors underrepresented researchers actively engaged or interested in joining the CCA research community, and encourages networking with international CCA research consortiums and patient advocacy organizations. The ultimate aim is to advance new and effective strategies for greatly reducing the human impact of this highly fatal malignancy.

项目摘要/摘要 胆管癌（CCA）是一种宏观分子多样的肝甲状腺毛道恶性肿瘤 约占胃肠道恶性肿瘤的3.0％，占10％至20％ 原发性肝癌。在过去的10 - 20年中，CCA已成为增强的重点 兴趣和关注，在很大程度上是由于现在已公认的越来越多的发病率 全球各个国家以及CCA的全球范围内的CCA内部CCA 包括美国在内的世界几个地区的死亡率也在上升。大多数CCA患者 被诊断出患有晚期疾病，治疗方案有限，总体5年 生存率很沮丧。但是，越来越多的目标疗法的最新进展 临床试验为改善高级CCA的生存结果提供了一些希望 患者。据我们所知，这次FaseB科学会议代表了首先的4-- 人身全面的科学会议仅专门致力于CCA。它汇集了一个 多元化的高级和才华横溢的早期职业调查员批判性评估重要 当前和不断发展的基本，翻译和临床研究的领域侧重于解决 继续将进步限制为取得重大改进的主要挑战 在CCA预防，临床管理和患者生存结果中。关键主题领域 将解决（1）肿瘤间和肿瘤内异质性的挑战，（2） 微生物组和肿瘤微环境在影响疾病进程中的作用， 治疗性抗性和免疫监视，（3）细胞起源，谱系和基因组 CCA与肝细胞癌之间的关系，（4）新颖和更多的鉴定 有效的生物标志物签名，用于早期CCA检测和监测发病症和 治疗； （5）个性化疗法的“多态”的进步，（6）创新的临床前 CCA药物发现的建模，（7）CCA个性化的当前和新兴趋势 医学和（8）探索CCA疗法的新技术和方法。额外的 这次急需的会议的重要目的涉及提供合作和协作 支持早期职业研究者发展的环境，促进科学串扰 在不同的科学学科和临床学科之间，导师代表性的研究人员不足 积极参与或有兴趣加入CCA研究社区，并鼓励 与国际CCA研究联盟和患者倡导组织建立联系。 最终目的是推进新的有效策略，以大大减少人类 这种高度致命的恶性肿瘤的影响。